Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Philip Reigan

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-6431
    Other Positions
    TitleDirector-Faculty
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOP-Administration


    Collapse Research 
    Collapse research activities and funding
    R01CA251534     (REIGAN, PHILIP)Jul 1, 2021 - Jun 30, 2026
    NIH
    Development of AMPK Inhibitors for the treatment of leukemia
    Role: Principal Investigator

    R21NS084084     (REIGAN, PHILIP)Jul 15, 2013 - Jun 30, 2016
    NIH
    Novel small-molecule inhibitors of Wee1 kinase for medulloblastoma treatment
    Role: Principal Investigator

    R43DA036211     (TABAKOFF, BORIS)Jul 15, 2013 - Dec 31, 2015
    NIH
    A Delta/Kappa OR Ligand: Taking Advantage of Heteromers to Control Pain
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Eiler DR, Wimberly BT, Bilodeau DY, Taliaferro JM, Reigan P, Rissland OS, Kieft JS. The Giardia lamblia ribosome structure reveals divergence in several biological pathways and the mode of emetine function. Structure. 2024 Jan 11. PMID: 38242118.
      View in: PubMed
    2. Hussain A, Nguyen VT, Reigan P, McMurray M. Evolutionary degeneration of septins into pseudoGTPases: impacts on a hetero-oligomeric assembly interface. Front Cell Dev Biol. 2023; 11:1296657. PMID: 38125875.
      View in: PubMed
    3. Gates CA, Backos DS, Reigan P, Natale NR. The Lateral Metalation of Isoxazolo[3,4-d]pyridazinones towards Hit-to-Lead Development of Selective Positive Modulators of Metabotropic Glutamate Receptors. Molecules. 2023 Sep 25; 28(19). PMID: 37836643.
      View in: PubMed
    4. Warfield BM, Reigan P. Multifunctional role of thymidine phosphorylase in cancer: (Trends in Cancer, 8:6 p:482-493, 2022). Trends Cancer. 2023 Aug; 9(8):691. PMID: 37355411.
      View in: PubMed
    5. Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023 Apr-May; 27(4-5):361-371. PMID: 37243607.
      View in: PubMed
    6. Huynh TN, Shukla S, Reigan P, Parker R. Identification of PARN nuclease activity inhibitors by computational-based docking and high-throughput screening. Sci Rep. 2023 03 31; 13(1):5244. PMID: 37002320.
      View in: PubMed
    7. Oldham D, Wang H, Mullen J, Lietzke E, Sprenger K, Reigan P, Eckel RH, Bruce KD. Using Synthetic ApoC-II Peptides and nAngptl4 Fragments to Measure Lipoprotein Lipase Activity in Radiometric and Fluorescent Assays. Front Cardiovasc Med. 2022; 9:926631. PMID: 35911520.
      View in: PubMed
    8. Duncan NS, Campbell MJ, Backos DS, Li C, Rider KC, Stump S, Weaver MJ, Gajewski MP, Beall HD, Reigan P, Natale NR. 10-Alkoxy-anthracenyl-isoxazole analogs have sub-micromolar activity against a Glioblastoma multiforme cell line. Bioorg Med Chem. 2022 09 01; 69:116911. PMID: 35792402.
      View in: PubMed
    9. Kanai SM, Heffner C, Cox TC, Cunningham ML, Perez FA, Bauer AM, Reigan P, Carter C, Murray SA, Clouthier DE. Auriculocondylar syndrome 2 results from the dominant-negative action of PLCB4 variants. Dis Model Mech. 2022 04 01; 15(4). PMID: 35284927.
      View in: PubMed
    10. Warfield BM, Reigan P. Multifunctional role of thymidine phosphorylase in cancer. Trends Cancer. 2022 06; 8(6):482-493. PMID: 35193822.
      View in: PubMed
    11. Rocha SM, Fagre AC, Latham AS, Cummings JE, Aboellail TA, Reigan P, Aldaz DA, McDermott CP, Popichak KA, Kading RC, Schountz T, Theise ND, Slayden RA, Tjalkens RB. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection. Front Immunol. 2022; 13:811430. PMID: 35250984.
      View in: PubMed
    12. Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, Pollyea DA, Reigan P, Jordan CT. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022 01 27; 139(4):584-596. PMID: 34525179.
      View in: PubMed
    13. Warfield BM, Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Substituted pteridinones, pyrimidines, pyrrolopyrimidines, and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors: Pharmacophore modeling data. Data Brief. 2021 Oct; 38:107433. PMID: 34632023.
      View in: PubMed
    14. Warfield BM, Matheson CJ, McArthur DG, Backos DS, Reigan P. Evaluation of Thymidine Phosphorylase Inhibitors in Glioblastoma and Their Capacity for Temozolomide Potentiation. ACS Chem Neurosci. 2021 09 15; 12(18):3477-3486. PMID: 34472849.
      View in: PubMed
    15. Casalvieri KA, Matheson CJ, Warfield BM, Backos DS, Reigan P. N-Substituted pyrrolopyrimidines and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors. Bioorg Med Chem. 2021 07 01; 41:116220. PMID: 34034149.
      View in: PubMed
    16. Hicks HM, McKenna LR, Espinoza VL, Pozdeyev N, Pike LA, Sams SB, LaBarbera D, Reigan P, Raeburn CD, E Schweppe R. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021 03; 60(3):201-212. PMID: 33595872.
      View in: PubMed
    17. Anderson CC, Marentette JO, Rauniyar AK, Prutton KM, Khatri M, Matheson C, Reisz JA, Reigan P, D'Alessandro A, Roede JR. Maneb alters central carbon metabolism and thiol redox status in a toxicant model of Parkinson's disease. Free Radic Biol Med. 2021 01; 162:65-76. PMID: 33279619.
      View in: PubMed
    18. D Bruce K, Tang M, Reigan P, H Eckel R. Genetic Variants of Lipoprotein Lipase and Regulatory Factors Associated with Alzheimer's Disease Risk. Int J Mol Sci. 2020 Nov 06; 21(21). PMID: 33172164.
      View in: PubMed
    19. Weaver MJ, Stump S, Campbell MJ, Backos DS, Li C, Reigan P, Adams E, Beall HD, Natale NR. 10-N-heterocylic aryl-isoxazole-amides (AIMs) have robust anti-tumor activity against breast and brain cancer cell lines and useful fluorescence properties. Bioorg Med Chem. 2020 11 15; 28(22):115781. PMID: 33038788.
      View in: PubMed
    20. Matheson CJ, Casalvieri KA, Backos DS, Minhajuddin M, Jordan CT, Reigan P. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors. Eur J Med Chem. 2020 Jul 01; 197:112316. PMID: 32334266.
      View in: PubMed
    21. Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Molecular docking of substituted pteridinones and pyrimidines to the ATP-binding site of the N-terminal domain of RSK2 and associated MM/GBSA and molecular field datasets. Data Brief. 2020 Apr; 29:105347. PMID: 32211459.
      View in: PubMed
    22. Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study. Bioorg Med Chem. 2020 03 01; 28(5):115303. PMID: 31982240.
      View in: PubMed
    23. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048. PMID: 30733375.
      View in: PubMed
    24. Gates C, Backos DS, Reigan P, Kang HJ, Koerner C, Mirzaei J, Natale NR. Isoxazolo[3,4-d]pyridazinones positively modulate the metabotropic glutamate subtypes 2 and 4. Bioorg Med Chem. 2018 09 15; 26(17):4797-4803. PMID: 30143366.
      View in: PubMed
    25. Matheson CJ, Casalvieri KA, Backos DS, Reigan P. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. ChemMedChem. 2018 08 20; 13(16):1681-1694. PMID: 29883531.
      View in: PubMed
    26. Steiger SA, Li C, Backos DS, Reigan P, Natale NR. Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter. Bioorg Med Chem. 2017 06 15; 25(12):3223-3234. PMID: 28434782.
      View in: PubMed
    27. Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Selective Targeting of RSK Isoforms in Cancer. Trends Cancer. 2017 04; 3(4):302-312. PMID: 28718440.
      View in: PubMed
    28. Furtek SL, Matheson CJ, Backos DS, Reigan P. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. Oncotarget. 2016 Nov 22; 7(47):77998-78008. PMID: 27793003.
      View in: PubMed
    29. Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016 10; 37(10):872-881. PMID: 27427153.
      View in: PubMed
    30. Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. ACS Chem Biol. 2016 07 15; 11(7):2066-7. PMID: 27304454.
      View in: PubMed
    31. Furtek SL, Backos DS, Matheson CJ, Reigan P. Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol. 2016 Feb 19; 11(2):308-18. PMID: 26730496.
      View in: PubMed
    32. Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. ACS Chem Biol. 2016 Apr 15; 11(4):921-30. PMID: 26745241.
      View in: PubMed
    33. Xiong W, Matheson CJ, Xu M, Backos DS, Mills TS, Salian-Mehta S, Kiseljak-Vassiliades K, Reigan P, Wierman ME. Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors. Mol Cancer Ther. 2016 Mar; 15(3):412-20. PMID: 26721946.
      View in: PubMed
    34. Martinez EC, Passariello CL, Li J, Matheson CJ, Dodge-Kafka K, Reigan P, Kapiloff MS. RSK3: A regulator of pathological cardiac remodeling. IUBMB Life. 2015 May; 67(5):331-7. PMID: 25988524.
      View in: PubMed
    35. Weaver MJ, Kearns AK, Stump S, Li C, Gajewski MP, Rider KC, Backos DS, Reigan PR, Beall HD, Natale NR. AIMing towards improved antitumor efficacy. Bioorg Med Chem Lett. 2015 Apr 15; 25(8):1765-1770. PMID: 25782743.
      View in: PubMed
    36. Jackson BC, Reigan P, Miller B, Thompson DC, Vasiliou V. Human ALDH1B1 polymorphisms may affect the metabolism of acetaldehyde and all-trans retinaldehyde--in vitro studies and computational modeling. Pharm Res. 2015 May; 32(5):1648-62. PMID: 25413692.
      View in: PubMed
    37. Galligan JJ, Fritz KS, Backos DS, Shearn CT, Smathers RL, Jiang H, MacLean KN, Reigan PR, Petersen DR. Oxidative stress-mediated aldehyde adduction of GRP78 in a mouse model of alcoholic liver disease: functional independence of ATPase activity and chaperone function. Free Radic Biol Med. 2014 Aug; 73:411-20. PMID: 24924946.
      View in: PubMed
    38. Krueger AB, Drasin DJ, Lea WA, Patrick AN, Patnaik S, Backos DS, Matheson CJ, Hu X, Barnaeva E, Holliday MJ, Blevins MA, Robin TP, Eisenmesser EZ, Ferrer M, Simeonov A, Southall N, Reigan P, Marugan J, Ford HL, Zhao R. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration. J Biol Chem. 2014 Jun 06; 289(23):16349-61. PMID: 24755226.
      View in: PubMed
    39. Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, Reigan P, Vibhakar R. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer. 2014 Mar 24; 13:72. PMID: 24661910.
      View in: PubMed
    40. Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013 Dec; 12(12):2675-84. PMID: 24121103.
      View in: PubMed
    41. Shearn CT, Smathers RL, Backos DS, Reigan P, Orlicky DJ, Petersen DR. Increased carbonylation of the lipid phosphatase PTEN contributes to Akt2 activation in a murine model of early alcohol-induced steatosis. Free Radic Biol Med. 2013 Dec; 65:680-692. PMID: 23872024.
      View in: PubMed
    42. Backos DS, Fritz KS, McArthur DG, Kepa JK, Donson AM, Petersen DR, Foreman NK, Franklin CC, Reigan P. Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma. Neurochem Res. 2013 Sep; 38(9):1838-49. PMID: 23743623.
      View in: PubMed
    43. Sun AQ, Luo Y, Backos DS, Xu S, Balasubramaniyan N, Reigan P, Suchy FJ. Identification of functionally relevant lysine residues that modulate human farnesoid X receptor activation. Mol Pharmacol. 2013 May; 83(5):1078-86. PMID: 23462506.
      View in: PubMed
    44. Vasiliou V, Sandoval M, Backos DS, Jackson BC, Chen Y, Reigan P, Lanaspa MA, Johnson RJ, Koppaka V, Thompson DC. ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1. Chem Biol Interact. 2013 Feb 25; 202(1-3):22-31. PMID: 23348497.
      View in: PubMed
    45. Jackson BC, Holmes RS, Backos DS, Reigan P, Thompson DC, Vasiliou V. Comparative genomics, molecular evolution and computational modeling of ALDH1B1 and ALDH2. Chem Biol Interact. 2013 Feb 25; 202(1-3):11-21. PMID: 23247008.
      View in: PubMed
    46. Ryan K, Backos DS, Reigan P, Patel M. Post-translational oxidative modification and inactivation of mitochondrial complex I in epileptogenesis. J Neurosci. 2012 Aug 15; 32(33):11250-8. PMID: 22895709.
      View in: PubMed
    47. Sarsour EH, Kalen AL, Xiao Z, Veenstra TD, Chaudhuri L, Venkataraman S, Reigan P, Buettner GR, Goswami PC. Manganese superoxide dismutase regulates a metabolic switch during the mammalian cell cycle. Cancer Res. 2012 Aug 01; 72(15):3807-16. PMID: 22710435.
      View in: PubMed
    48. Smathers RL, Fritz KS, Galligan JJ, Shearn CT, Reigan P, Marks MJ, Petersen DR. Characterization of 4-HNE modified L-FABP reveals alterations in structural and functional dynamics. PLoS One. 2012; 7(6):e38459. PMID: 22701647.
      View in: PubMed
    49. Shearn CT, Reigan P, Petersen DR. Inhibition of hydrogen peroxide signaling by 4-hydroxynonenal due to differential regulation of Akt1 and Akt2 contributes to decreases in cell survival and proliferation in hepatocellular carcinoma cells. Free Radic Biol Med. 2012 Jul 01; 53(1):1-11. PMID: 22580126.
      View in: PubMed
    50. Backos DS, Franklin CC, Reigan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol. 2012 Apr 15; 83(8):1005-12. PMID: 22138445.
      View in: PubMed
    51. Ponder J, Yoo BH, Abraham AD, Li Q, Ashley AK, Amerin CL, Zhou Q, Reid BG, Reigan P, Hromas R, Nickoloff JA, LaBarbera DV. Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIa activity through ATP-competitive inhibition. Mar Drugs. 2011; 9(11):2397-2408. PMID: 22163192.
      View in: PubMed
    52. Yan C, Dufour M, Siegel D, Reigan P, Gomez J, Shieh B, Moody CJ, Ross D. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems. Biochemistry. 2011 Aug 09; 50(31):6678-88. PMID: 21718050.
      View in: PubMed
    53. Chong BM, Reigan P, Mayle-Combs KD, Orlicky DJ, McManaman JL. Determinants of adipophilin function in milk lipid formation and secretion. Trends Endocrinol Metab. 2011 Jun; 22(6):211-7. PMID: 21592818.
      View in: PubMed
    54. Shearn CT, Fritz KS, Reigan P, Petersen DR. Modification of Akt2 by 4-hydroxynonenal inhibits insulin-dependent Akt signaling in HepG2 cells. Biochemistry. 2011 May 17; 50(19):3984-96. PMID: 21438592.
      View in: PubMed
    55. Dufour M, Yan C, Siegel D, Colucci MA, Jenner M, Oldham NJ, Gomez J, Reigan P, Li Y, De Matteis CI, Ross D, Moody CJ. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition. Chembiochem. 2011 May 16; 12(8):1203-8. PMID: 21506232.
      View in: PubMed
    56. Fritz KS, Galligan JJ, Smathers RL, Roede JR, Shearn CT, Reigan P, Petersen DR. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol. 2011 May 16; 24(5):651-62. PMID: 21449565.
      View in: PubMed
    57. Chong BM, Russell TD, Schaack J, Orlicky DJ, Reigan P, Ladinsky M, McManaman JL. The adipophilin C terminus is a self-folding membrane-binding domain that is important for milk lipid secretion. J Biol Chem. 2011 Jul 01; 286(26):23254-65. PMID: 21383012.
      View in: PubMed
    58. Reigan P, Siegel D, Guo W, Ross D. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins. Mol Pharmacol. 2011 May; 79(5):823-32. PMID: 21285336.
      View in: PubMed
    59. Yan C, Shieh B, Reigan P, Zhang Z, Colucci MA, Chilloux A, Newsome JJ, Siegel D, Chan D, Moody CJ, Ross D. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target. Mol Pharmacol. 2009 Jul; 76(1):163-72. PMID: 19364812.
      View in: PubMed
    60. Roede JR, Carbone DL, Doorn JA, Kirichenko OV, Reigan P, Petersen DR. In vitro and in silico characterization of peroxiredoxin 6 modified by 4-hydroxynonenal and 4-oxononenal. Chem Res Toxicol. 2008 Dec; 21(12):2289-99. PMID: 19548352.
      View in: PubMed
    61. Guo W, Reigan P, Siegel D, Ross D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos. 2008 Oct; 36(10):2050-7. PMID: 18635747.
      View in: PubMed
    62. Colucci MA, Reigan P, Siegel D, Chilloux A, Ross D, Moody CJ. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity. J Med Chem. 2007 Nov 15; 50(23):5780-9. PMID: 17944451.
      View in: PubMed
    63. Reigan P, Gbaj A, Stratford IJ, Bryce RA, Freeman S. Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors. Eur J Med Chem. 2008 Jun; 43(6):1248-60. PMID: 17870212.
      View in: PubMed
    64. Lambert C, Li J, Jonscher K, Yang TC, Reigan P, Quintana M, Harvey J, Freed BM. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. J Biol Chem. 2007 Jul 06; 282(27):19666-75. PMID: 17491020.
      View in: PubMed
    65. Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, Ross D. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry. 2007 May 22; 46(20):5941-50. PMID: 17455910.
      View in: PubMed
    66. Fang L, Battisti RF, Cheng H, Reigan P, Xin Y, Shen J, Ross D, Chan KK, Martin EW, Wang PG, Sun D. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J Med Chem. 2006 Oct 19; 49(21):6290-7. PMID: 17034135.
      View in: PubMed
    67. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol. 2006 Oct; 70(4):1194-203. PMID: 16825487.
      View in: PubMed
    68. Dehn DL, Siegel D, Zafar KS, Reigan P, Swann E, Moody CJ, Ross D. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Mol Cancer Ther. 2006 Jul; 5(7):1702-9. PMID: 16891456.
      View in: PubMed
    69. Gbaj A, Edwards PN, Reigan P, Freeman S, Jaffar M, Douglas KT. Thymidine phosphorylase from Escherichia coli: tight-binding inhibitors as enzyme active-site titrants. J Enzyme Inhib Med Chem. 2006 Feb; 21(1):69-73. PMID: 16570508.
      View in: PubMed
    70. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 2005 Nov 01; 65(21):10006-15. PMID: 16267026.
      View in: PubMed
    71. Reigan P, Edwards PN, Gbaj A, Cole C, Barry ST, Page KM, Ashton SE, Luke RW, Douglas KT, Stratford IJ, Jaffar M, Bryce RA, Freeman S. Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. J Med Chem. 2005 Jan 27; 48(2):392-402. PMID: 15658853.
      View in: PubMed
    72. Reigan P, Gbaj A, Chinje E, Stratford IJ, Douglas KT, Freeman S. Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2004 Nov 01; 14(21):5247-50. PMID: 15454205.
      View in: PubMed
    73. Cole C, Reigan P, Gbaj A, Edwards PN, Douglas KT, Stratford IJ, Freeman S, Jaffar M. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. J Med Chem. 2003 Jan 16; 46(2):207-9. PMID: 12519058.
      View in: PubMed
    Reigan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)